Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus Erythematosus

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Dong, Guang Fu ^a   Zhang, Xiao ^a   He, De Ning ^a,b   Li, Ling ^a   Zhang, Guang Feng ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Pingxiang People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD38 ANTIGEN; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; F ACTIN; FAS ANTIGEN; IMMUNOGLOBULIN D; LEFLUNOMIDE; TERIFLUNOMIDE; ACTIN; ANILINE DERIVATIVE; HYDROXYBUTYRIC ACID; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; LEUKOCYTE ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID RAFT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; CASE CONTROL STUDY; CELL MEMBRANE; DRUG EFFECTS; IMMUNOLOGY;

ACTINS; ADULT; ANILINE COMPOUNDS; ANTIGENS, CD; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYBUTYRATES; IMMUNOGLOBULIN D; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE MICRODOMAINS;

EID: 84930958482     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/832916     Document Type: Article

References (31)

1. J. H. Anolik, "B cell biology: implications for treatment of systemic lupus erythematosus," Lupus, vol. 22, no. 4, pp. 342-349, 2013.
2. M. Gatto, M. Zen, A. Ghirardello et al., "Emerging and critical issues in the pathogenesis of lupus," Autoimmunity Reviews, vol. 12, no. 4, pp. 523-536, 2013.
3. V. Paunovic, N. A. Carter, T. Thalhamer et al., "Immune complex-mediated co-ligation of the BCR with FcγRIIB results in homeostatic apoptosis of B cells involving Fas signalling that is defective in the MRL/Lpr model of systemic lupus erythematosus," Journal of Autoimmunity, vol. 39, no. 4, pp. 332-346, 2012.
4. L. P. Kil, M. J. W. de Bruijn, M. van Nimwegen et al., "Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice," Blood, vol. 119, no. 16, pp. 3744-3756, 2012.
5. N. Jacob, S. Guo, A. Mathian et al., "B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice," Journal of Immunology, vol. 186, no. 8, pp. 4984-4993, 2011.
6. K. Simons and E. Ikonen, "Functional rafts in cell membranes,"Nature, vol. 387, no. 6633, pp. 569-572, 1997.
7. N. Gupta and A. L. DeFranco, "Lipid rafts and B cell signaling,"Seminars in Cell and Developmental Biology, vol. 18, no. 5, pp. 616-626, 2007.
8. S. A. Freeman, V. Lei, M. Dang-Lawson, K. Mizuno, C. D. Roskelley, and M. R. Gold, "Cofilin-mediated F-actin severing is regulated by the Rap GTPase and controls the cytoskeletal dynamics that drive lymphocyte spreading and BCR microcluster formation," The Journal of Immunology, vol. 187, no. 11, pp. 5887-5900, 2011.
9. D. Holowka, E. D. Sheets, and B. Baird, "Interactions between FcεRI and lipid raft components are regulated by the actin cytoskeleton," Journal of Cell Science, vol. 113, no. 6, pp. 1009-1019, 2000.
10. S. Krishnan, M. P. Nambiar, V. G. Warke et al., "Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus," The Journal of Immunology, vol. 172, no. 12, pp. 7821-7831, 2004.
11. G.-M. Deng and G. C. Tsokos, "Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation," The Journal of Immunology, vol. 181, no. 6, pp. 4019-4026, 2008.
12. E. C. Jury, P. S. Kabouridis, F. Flores-Borja, R. A. Mageed, and D. A. Isenberg, "Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus," The Journal of Clinical Investigation, vol. 113, no. 8, pp. 1176-1187, 2004.
13. G. McDonald, S. Deepak, L. Miguel et al., "Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients," Journal of Clinical Investigation, vol. 124, no. 2, pp. 712-724, 2014.
14. F. Flores-Borja, P. S. Kabouridis, E. C. Jury, D. A. Isenberg, and R. A. Mageed, "Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus,"Arthritis & Rheumatism, vol. 56, no. 1, pp. 291-302, 2007.
15. G.-C. Wu, X.-D. Xu, Q. Huang, and H. Wu, "Leflunomide: friend or foe for systemic lupus erythematosus?" Rheumatology International, vol. 33, no. 2, pp. 273-276, 2013.
16. F. C. Breedveld and J.-M. Dayer, "Leflunomide: mode of action in the treatment of rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 59, no. 11, pp. 841-849, 2000.
17. M. C. Hochberg, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus," Arthritis & Rheumatism, vol. 40, no. 9, p. 1725, 1997.
18. C. Vitali, S. Bombardieri, R. Jonsson et al., "Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group," Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554-558, 2002.
19. C. Bombardier, D. D. Gladman, M. B. Urowitz et al., "Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE," Arthritis & Rheumatism, vol. 35, no. 6, pp. 630-640, 1992.
20. N. Blank, M. Schiller, S. Krienke, G. Wabnitz, A. D. Ho, and H.-M. Lorenz, "Cholera toxin binds to lipid rafts but has a limited specificity for ganglioside GM1," Immunology and Cell Biology, vol. 85, no. 5, pp. 378-382, 2007.
21. P. W. Janes, S. C. Ley, and A. I. Magee, "Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor," The Journal of Cell Biology, vol. 147, no. 2, pp. 447-461, 1999.
22. M. M. Rosado, A. P. Diamanti, F. Capolunghi, and R. Carsetti, "B cell modulation strategies in autoimmunity: the SLE example,"Current Pharmaceutical Design, vol. 17, no. 29, pp. 3155-3165, 2011.
23. C. Wei, J. Anolik, A. Cappione et al., "A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus,"The Journal of Immunology, vol. 178, no. 10, pp. 6624-6633, 2007.
24. M. E. Peter, R. C. Budd, J. Desbarats et al., "The CD95 receptor: apoptosis revisited," Cell, vol. 129, no. 3, pp. 447-450, 2007.
25. S. A. Jenks and I. Sanz, "Altered B cell receptor signaling in human systemic lupus erythematosus," Autoimmunity Reviews, vol. 8, no. 3, pp. 209-213, 2009.
26. N. Gupta and A. L. DeFranco, "Visualizing lipid raft dynamics and early signaling events during antigen receptor-mediated B-lymphocyte activation," Molecular Biology of the Cell, vol. 14, no. 2, pp. 432-444, 2003.
27. A. Grahnert, C. Klein, E. Schilling, J. Wehrhahn, and S. Hauschildt, "NAD+: a modulator of immune functions," Innate Immunity, vol. 17, no. 2, pp. 212-223, 2011.
28. S. Hao and A. August, "Actin depolymerization transduces the strength of B-cell receptor stimulation," Molecular Biology of the Cell, vol. 16, no. 5, pp. 2275-2284, 2005.
29. R. Sweet, S. Mahdavian, A. Singh, P. Ghazvini, T. McKinnon, and D. Jones, "An update on the management of systemic lupus erythematosus," Journal of Hematological Malignancies, vol. 3, no. 2, pp. 16-23, 2013.
30. S. Kalloo, N. Aggarwal, P. Mohan, and J. Radhakrishnan, "Lupus nephritis: treatment of resistant disease," Clinical Journal of the American Society of Nephrology, vol. 8, no. 1, pp. 154-161, 2013.
31. F. S. Zhang, Y. K. Nie, X. M. Jin, H. M. Yu, Y. N. Li, and Y. Sun, "The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy," Rheumatology International, vol. 29, no. 11, pp. 1331-1335, 2009.